Literature DB >> 23934186

The Yin and Yang of Toll-like receptors in cancer.

J-P Pradere1, D H Dapito2, R F Schwabe2.   

Abstract

Recognition of non-self molecular patterns by pattern recognition receptors is a cornerstone of innate immunity. Toll-like receptors (TLRs) exert a key role in recognizing pathogen-associated molecular patterns (PAMPs) but have also been implicated in the recognition of damage-associated molecular patterns (DAMPs). As such, TLRs regulate a wide range of biological responses including inflammatory and immune responses during carcinogenesis. The high expression of TLRs by antigen-presenting cells, including dendritic cells, and their ability to induce antitumor mediators such as type I interferon has led to efforts to utilize TLR agonists in tumor therapy in order to convert the often tolerant immune response toward antitumor responses. However, TLRs are also increasingly recognized as regulators of tumor-promoting inflammation and promoters of tumor survival signals. Here, we will review in detail the dichotomous role of TLRs in tumor biology, focusing on relevant TLR-dependent pro- and antitumor pathways, and discuss clinical applications of TLR-targeted therapies for tumor prevention and treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23934186      PMCID: PMC4059777          DOI: 10.1038/onc.2013.302

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  184 in total

1.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

2.  Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis.

Authors:  Masayuki Fukata; Limin Shang; Rebeca Santaolalla; John Sotolongo; Cristhine Pastorini; Cecilia España; Ryan Ungaro; Noam Harpaz; Harry S Cooper; Greg Elson; Marie Kosco-Vilbois; Julia Zaias; Maria T Perez; Lloyd Mayer; Arunan S Vamadevan; Sergio A Lira; Maria T Abreu
Journal:  Inflamm Bowel Dis       Date:  2010-11-15       Impact factor: 5.325

Review 3.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

4.  TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells.

Authors:  Deepak Mittal; Fabiana Saccheri; Emilie Vénéreau; Tobias Pusterla; Marco E Bianchi; Maria Rescigno
Journal:  EMBO J       Date:  2010-06-04       Impact factor: 11.598

Review 5.  Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage.

Authors:  Sergei I Grivennikov; Michael Karin
Journal:  Ann Rheum Dis       Date:  2011-03       Impact factor: 19.103

Review 6.  Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Authors:  Lisa M Coussens; Laurence Zitvogel; A Karolina Palucka
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

7.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

Review 8.  Tumour immunity: effector response to tumour and role of the microenvironment.

Authors:  Alberto Mantovani; Pedro Romero; A Karolina Palucka; Francesco M Marincola
Journal:  Lancet       Date:  2008-02-13       Impact factor: 79.321

9.  Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors.

Authors:  Masayuki Fukata; Yasmin Hernandez; Daisy Conduah; Jason Cohen; Anli Chen; Keith Breglio; Tyralee Goo; David Hsu; Ruliang Xu; Maria T Abreu
Journal:  Inflamm Bowel Dis       Date:  2009-07       Impact factor: 5.325

10.  Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll-like receptor 2-deficient mice.

Authors:  Heng Lin; Jun Yan; Ziyan Wang; Fang Hua; Jiaojiao Yu; Wei Sun; Ke Li; Hong Liu; Hongzhen Yang; Qi Lv; Jianfei Xue; Zhuo-Wei Hu
Journal:  Hepatology       Date:  2013-01       Impact factor: 17.425

View more
  109 in total

1.  Glioblastoma Cancer Stem Cells Evade Innate Immune Suppression of Self-Renewal through Reduced TLR4 Expression.

Authors:  Alvaro G Alvarado; Praveena S Thiagarajan; Erin E Mulkearns-Hubert; Daniel J Silver; James S Hale; Tyler J Alban; Soumya M Turaga; Awad Jarrar; Ofer Reizes; Michelle S Longworth; Michael A Vogelbaum; Justin D Lathia
Journal:  Cell Stem Cell       Date:  2017-01-12       Impact factor: 24.633

2.  A Structural View of Negative Regulation of the Toll-like Receptor-Mediated Inflammatory Pathway.

Authors:  Emine Guven-Maiorov; Ozlem Keskin; Attila Gursoy; Ruth Nussinov
Journal:  Biophys J       Date:  2015-08-11       Impact factor: 4.033

3.  Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis.

Authors:  Elisabetta Vulpis; Francesca Cecere; Rosa Molfetta; Alessandra Soriani; Cinzia Fionda; Giovanna Peruzzi; Giulio Caracciolo; Sara Palchetti; Laura Masuelli; Lucilla Simonelli; Ugo D'Oro; Maria Pia Abruzzese; Maria Teresa Petrucci; Maria Rosaria Ricciardi; Rossella Paolini; Marco Cippitelli; Angela Santoni; Alessandra Zingoni
Journal:  Oncoimmunology       Date:  2017-01-13       Impact factor: 8.110

4.  Colon carcinogenesis in wild type and immune compromised mice after treatment with azoxymethane, and azoxymethane with dextran sodium sulfate.

Authors:  Ryan D Whetstone; Uwe A Wittel; Nicole M Michels; James M Gulizia; Barry Gold
Journal:  Mol Carcinog       Date:  2015-07-08       Impact factor: 4.784

5.  File Compression and Expansion of the Genetic Code by the use of the Yin/Yang Directions to find its Sphered Cube.

Authors:  Fernando Castro-Chavez
Journal:  J Biodivers Bioprospect Dev       Date:  2014-07

Review 6.  Recent advancement in understanding colitis-associated tumorigenesis.

Authors:  Daren Low; Mari Mino-Kenudson; Emiko Mizoguchi
Journal:  Inflamm Bowel Dis       Date:  2014-11       Impact factor: 5.325

Review 7.  Microbiota in cancer development and treatment.

Authors:  Muhammad Hassan Raza; Kamni Gul; Abida Arshad; Naveeda Riaz; Usman Waheed; Abdul Rauf; Fahad Aldakheel; Shatha Alduraywish; Maqbool Ur Rehman; Muhammad Abdullah; Muhammad Arshad
Journal:  J Cancer Res Clin Oncol       Date:  2018-12-12       Impact factor: 4.553

Review 8.  Cytokines, IBD, and colitis-associated cancer.

Authors:  Ralph Francescone; Vivianty Hou; Sergei I Grivennikov
Journal:  Inflamm Bowel Dis       Date:  2015-02       Impact factor: 5.325

Review 9.  Protective Innate Immune Variants in Racial/Ethnic Disparities of Breast and Prostate Cancer.

Authors:  LaCreis R Kidd; K Sean Kimbro; Susan T Yeyeodu
Journal:  Cancer Immunol Res       Date:  2019-09       Impact factor: 11.151

10.  Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.

Authors:  Satoshi Okazaki; Fotios Loupakis; Sebastian Stintzing; Shu Cao; Wu Zhang; Dongyun Yang; Yan Ning; Yu Sunakawa; Stefan Stremitzer; Satoshi Matsusaka; Martin D Berger; Anish Parekh; Jordan D West; Yuji Miyamoto; Mitsukuni Suenaga; Marta Schirripa; Chiara Cremolini; Alfredo Falcone; Volker Heinemann; R William DePaolo; Heinz-Josef Lenz
Journal:  Mol Cancer Ther       Date:  2016-05-11       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.